Search Browse Earnings

KALA BIO, Inc.

Nasdaq:KALA

Pharmaceutical Preparations·ARLINGTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Lazar David E.

Revenue

$45,000

FY 2017

Adj. EBITDA

-$39.4M

-87466.7% margin

FY 2024

Net Income

-$42.2M

-93775.6% margin

FY 2024

EPS (Diluted)

-$17.35

FY 2024

Stock Price

$0.36

+21.7%

2026-03-11

52W Range

$0.23 – $20.60

P/E Ratio

-0.0x

Market Cap

$3.0M

Cash

$50.9M

FY 2024

Total Debt

$34.2M

FY 2024

Net Cash

$16.7M

FY 2024

Enterprise Value

-$13.7M

Debt / EBITDA

0.4x

FY 2017

EV / EBITDA

0.3x

Employees

—